These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 8758143)

  • 21. Decreased antimony uptake and overexpression of genes of thiol metabolism are associated with drug resistance in a canine isolate of Leishmania infantum.
    Gómez Pérez V; García-Hernandez R; Corpas-López V; Tomás AM; Martín-Sanchez J; Castanys S; Gamarro F
    Int J Parasitol Drugs Drug Resist; 2016 Aug; 6(2):133-9. PubMed ID: 27317865
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Liposomal amphotericin B in the treatment of visceral leishmaniasis in immunocompetent patients.
    Minodier P; Retornaz K; Horelt A; Garnier JM
    Fundam Clin Pharmacol; 2003 Apr; 17(2):183-8. PubMed ID: 12667228
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Oral leishmaniasis in an HIV-positive patient caused by two different zymodemes of Leishmania infantum.
    Cortés P; Cardeñosa N; Romaní J; Gállego M; Muñoz C; Barrio JL; Riera C; Portús M
    Trans R Soc Trop Med Hyg; 1997; 91(4):438-9. PubMed ID: 9373646
    [No Abstract]   [Full Text] [Related]  

  • 24. Recent advances in the treatment of visceral leishmaniasis.
    Davidson RN; Croft SL
    Trans R Soc Trop Med Hyg; 1993; 87(2):130-1, 141. PubMed ID: 8393221
    [No Abstract]   [Full Text] [Related]  

  • 25. Activity of IFN-gamma in experimental Leishmania infantum murine visceral leishmaniasis.
    Garin YJ; Sulahian A; Gangneux JP; Derouin F
    Pathol Biol (Paris); 1997 Jan; 45(1):48-51. PubMed ID: 9097846
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluation of the in vitro and in vivo antileishmanial activity of a chloroquinolin derivative against Leishmania species capable of causing tegumentary and visceral leishmaniasis.
    Soyer TG; Mendonça DVC; Tavares GSV; Lage DP; Dias DS; Ribeiro PAF; Perin L; Ludolf F; Coelho VTS; Ferreira ACG; Neves PHAS; Matos GF; Chávez-Fumagalli MA; Coimbra ES; Pereira GR; Coelho EAF; Antinarelli LMR
    Exp Parasitol; 2019 Apr; 199():30-37. PubMed ID: 30817917
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Therapeutic Efficacy of a Mixed Formulation of Conventional and PEGylated Liposomes Containing Meglumine Antimoniate, Combined with Allopurinol, in Dogs Naturally Infected with Leishmania infantum.
    Dos Santos CCP; Ramos GS; De Paula RC; Faria KF; Moreira POL; Pereira RA; Melo MN; Tafuri WL; Demicheli C; Ribeiro RR; Azevedo EG; Do Monte-Neto R; Da Silva SM; Frézard F
    Antimicrob Agents Chemother; 2020 Jun; 64(7):. PubMed ID: 32284386
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Two cases of visceral leishmaniasis in Colombia resistant to meglumine antimonial treatment.
    Vélez ID; Colmenares LM; Muñoz CA
    Rev Inst Med Trop Sao Paulo; 2009; 51(4):231-6. PubMed ID: 19739006
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Amphotericin B lipid complex versus meglumine antimoniate in the treatment of visceral leishmaniasis in patients infected with HIV: a randomized pilot study.
    Laguna F; Videla S; Jiménez-Mejías ME; Sirera G; Torre-Cisneros J; Ribera E; Prados D; Clotet B; Sust M; López-Vélez R; Alvar J;
    J Antimicrob Chemother; 2003 Sep; 52(3):464-8. PubMed ID: 12888588
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Increased Leishmania infantum resistance to miltefosine and amphotericin B after treatment of a dog with miltefosine and allopurinol.
    Gonçalves G; Campos MP; Gonçalves AS; Medeiros LCS; Figueiredo FB
    Parasit Vectors; 2021 Dec; 14(1):599. PubMed ID: 34886876
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Visceral leishmaniasis during pregnancy treated with meglumine antimoniate.
    Utili R; Rambaldi A; Tripodi MF; Andreana A
    Infection; 1995; 23(3):182-3. PubMed ID: 7499009
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparing the therapeutic efficacy of different amphotericin B-carrying delivery systems against visceral leishmaniasis.
    Mendonça DVC; Martins VT; Lage DP; Dias DS; Ribeiro PAF; Carvalho AMRS; Dias ALT; Miyazaki CK; Menezes-Souza D; Roatt BM; Tavares CAP; Barichello JM; Duarte MC; Coelho EAF
    Exp Parasitol; 2018 Mar; 186():24-35. PubMed ID: 29448040
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Polycaprolactone Antimony Nanoparticles as Drug Delivery System for Leishmaniasis.
    Sousa-Batista AJ; Cerqueira-Coutinho C; do Carmo FS; Albernaz MS; Santos-Oliveira R
    Am J Ther; 2019; 26(1):e12-e17. PubMed ID: 30601770
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Visceral leishmaniasis treatment, Italy.
    Gradoni L; Gramiccia M; Scalone A
    Emerg Infect Dis; 2003 Dec; 9(12):1617-20. PubMed ID: 14720406
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Novel methods for the encapsulation of meglumine antimoniate into liposomes.
    Frézard F; Michalick MS; Soares CF; Demicheli C
    Braz J Med Biol Res; 2000 Jul; 33(7):841-6. PubMed ID: 10881061
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Serological and parasitological follow-up in dogs experimentally infected with Leishmania infantum and treated with meglumine antimoniate.
    Riera C; Valladares JE; Gállego M; Aisa MJ; Castillejo S; Fisa R; Ribas N; Carrió J; Alberola J; Arboix M
    Vet Parasitol; 1999 Jul; 84(1-2):33-47. PubMed ID: 10435789
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Canine visceral leishmaniasis: comparison of in vitro leishmanicidal activity of marbofloxacin, meglumine antimoniate and sodium stibogluconate.
    Vouldoukis I; Rougier S; Dugas B; Pino P; Mazier D; Woehrlé F
    Vet Parasitol; 2006 Jan; 135(2):137-46. PubMed ID: 16242844
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In vivo antileishmanial activity and histopathological evaluation in Leishmania infantum infected hamsters after treatment with a furoxan derivative.
    de Almeida L; Passalacqua TG; Dutra LA; Fonseca JNVD; Nascimento RFQ; Imamura KB; de Andrade CR; Dos Santos JL; Graminha MAS
    Biomed Pharmacother; 2017 Nov; 95():536-547. PubMed ID: 28866421
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Discontinuation of secondary anti-leishmania prophylaxis in HIV-infected patients who have responded to highly active antiretroviral therapy.
    Berenguer J; Cosín J; Miralles P; López JC; Padilla B
    AIDS; 2000 Dec; 14(18):2946-8. PubMed ID: 11153679
    [No Abstract]   [Full Text] [Related]  

  • 40. [Canine leishmaniasis: evolution of the chemotherapeutic protocols].
    Oliva G; Foglia Manzillo V; Pagano A
    Parassitologia; 2004 Jun; 46(1-2):231-4. PubMed ID: 15305724
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.